Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

André, Pascale; Denis, Caroline; Soulas, Caroline; Bourbon-Caillet, Clarisse; Lopez, Julie; Arnoux, Thomas; Bléry, Mathieu; Bonnafous, Cécile; Gauthier, Laurent; Morel, Ariane; Rossi, Benjamín; Remark, Romain; Breso, Violette; Bonnet, Elodie; Habif, Guillaume; Guia, Sophie; I. Lalanne, Ana; Hoffmann, Caroline; Lantz, Olivier; Fayette, Jérôme; Boyer-Chammard, Agnès; Zerbib, Robert; Dodion, P.; Ghadially, Hormas; Jure‐Kunkel, Maria; Morel, Yannis; Herbst, Ronald; Narni-Mancinelli, Émilie; B. Cohen, Roger; Vivier, Éric

doi:10.1016/j.cell.2018.10.014

Public

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

Published in Cell • Nov 29, 2018

Authors:

Pascale André

Caroline Denis

Caroline Soulas

Abstract

T cell function in combination with PD-x axis blockade. Monalizumab also stimulated NK cell activity against antibody-coated target cells. Interim results of a phase II trial of monalizumab plus cetuximab in previously treated squamous cell carcinoma of the head and neck showed a 31% objective respo...

Subject

Biology

Cancer research

Effector

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!